VEGF localisation in diabetic retinopathy

Mike Boulton, David Foreman, Gillian Williams, David McLeod

Research output: Contribution to journalArticle

164 Citations (Scopus)

Abstract

Aim - To determine the staining pattern of vascular endothelial growth factor (VEGF) at different stages of diabetic retinopathy (including post-laser photocoagulation) and to compare staining in excised fibrovascular and fibrocellular (non-diabetic) preretinal membranes. Methods - Immunohistochemical localisation of VEGF, using antibodies raised against VEGF165 and VEGF was 121,165,189, carried out on specimens of normal human retina (n = 15), diabetic retinas ((a) with no overt retinopathy (n = 19), (b) with intraretinal vascular abnormalities but no proliferative retinopathy (n = 6), (c) with active proliferative retinopathy (n = 6), (d) with no residual proliferative retinopathy after photocoagulation therapy (n = 15)), excised diabetic fibrovascular membranes (n = 19), and non-diabetic fibrocellular membranes (n = 7). The degree and pattern of immunostaining was recorded. Results - In general, VEGF was absent from the majority of normal retinas. VEGF staining was apparent in most diabetic tissues but the staining pattern was dependent on both the specificity of the antibody used and the category of tissue. Staining with the VEGF165 antibody was generally confined to endothelial cells and perivascular regions while the VEGF121,165,189 antibody was also associated with extravascular components of the inner retina. Intensity of immunostaining of diabetic eyes was dependent on the severity of retinopathy being least in diabetics with no overt retinopathy and greatest in retinas with proliferative retinopathy. Interestingly, the intensity of immunostaining in diabetic retinas which had undergone laser surgery for proliferative retinopathy was reduced to basal levels. Moderate to intense immunostaining was observed in all fibrovascular and fibrocellular membranes examined. Conclusions - This study supports a circumstantial role for VEGF in the pathogenesis of both the preclinical and proliferative stages of diabetic retinopathy.

Original languageEnglish (US)
Pages (from-to)561-568
Number of pages8
JournalBritish Journal of Ophthalmology
Volume82
Issue number5
StatePublished - May 1998
Externally publishedYes

Fingerprint

Diabetic Retinopathy
Vascular Endothelial Growth Factor A
Retina
Staining and Labeling
Membranes
Light Coagulation
Antibodies
Antibody Specificity
Laser Therapy
Blood Vessels
Lasers
Endothelial Cells

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Boulton, M., Foreman, D., Williams, G., & McLeod, D. (1998). VEGF localisation in diabetic retinopathy. British Journal of Ophthalmology, 82(5), 561-568.

VEGF localisation in diabetic retinopathy. / Boulton, Mike; Foreman, David; Williams, Gillian; McLeod, David.

In: British Journal of Ophthalmology, Vol. 82, No. 5, 05.1998, p. 561-568.

Research output: Contribution to journalArticle

Boulton, M, Foreman, D, Williams, G & McLeod, D 1998, 'VEGF localisation in diabetic retinopathy', British Journal of Ophthalmology, vol. 82, no. 5, pp. 561-568.
Boulton M, Foreman D, Williams G, McLeod D. VEGF localisation in diabetic retinopathy. British Journal of Ophthalmology. 1998 May;82(5):561-568.
Boulton, Mike ; Foreman, David ; Williams, Gillian ; McLeod, David. / VEGF localisation in diabetic retinopathy. In: British Journal of Ophthalmology. 1998 ; Vol. 82, No. 5. pp. 561-568.
@article{2d396c5c9ab04ee4a6fad491f7864038,
title = "VEGF localisation in diabetic retinopathy",
abstract = "Aim - To determine the staining pattern of vascular endothelial growth factor (VEGF) at different stages of diabetic retinopathy (including post-laser photocoagulation) and to compare staining in excised fibrovascular and fibrocellular (non-diabetic) preretinal membranes. Methods - Immunohistochemical localisation of VEGF, using antibodies raised against VEGF165 and VEGF was 121,165,189, carried out on specimens of normal human retina (n = 15), diabetic retinas ((a) with no overt retinopathy (n = 19), (b) with intraretinal vascular abnormalities but no proliferative retinopathy (n = 6), (c) with active proliferative retinopathy (n = 6), (d) with no residual proliferative retinopathy after photocoagulation therapy (n = 15)), excised diabetic fibrovascular membranes (n = 19), and non-diabetic fibrocellular membranes (n = 7). The degree and pattern of immunostaining was recorded. Results - In general, VEGF was absent from the majority of normal retinas. VEGF staining was apparent in most diabetic tissues but the staining pattern was dependent on both the specificity of the antibody used and the category of tissue. Staining with the VEGF165 antibody was generally confined to endothelial cells and perivascular regions while the VEGF121,165,189 antibody was also associated with extravascular components of the inner retina. Intensity of immunostaining of diabetic eyes was dependent on the severity of retinopathy being least in diabetics with no overt retinopathy and greatest in retinas with proliferative retinopathy. Interestingly, the intensity of immunostaining in diabetic retinas which had undergone laser surgery for proliferative retinopathy was reduced to basal levels. Moderate to intense immunostaining was observed in all fibrovascular and fibrocellular membranes examined. Conclusions - This study supports a circumstantial role for VEGF in the pathogenesis of both the preclinical and proliferative stages of diabetic retinopathy.",
author = "Mike Boulton and David Foreman and Gillian Williams and David McLeod",
year = "1998",
month = "5",
language = "English (US)",
volume = "82",
pages = "561--568",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",
number = "5",

}

TY - JOUR

T1 - VEGF localisation in diabetic retinopathy

AU - Boulton, Mike

AU - Foreman, David

AU - Williams, Gillian

AU - McLeod, David

PY - 1998/5

Y1 - 1998/5

N2 - Aim - To determine the staining pattern of vascular endothelial growth factor (VEGF) at different stages of diabetic retinopathy (including post-laser photocoagulation) and to compare staining in excised fibrovascular and fibrocellular (non-diabetic) preretinal membranes. Methods - Immunohistochemical localisation of VEGF, using antibodies raised against VEGF165 and VEGF was 121,165,189, carried out on specimens of normal human retina (n = 15), diabetic retinas ((a) with no overt retinopathy (n = 19), (b) with intraretinal vascular abnormalities but no proliferative retinopathy (n = 6), (c) with active proliferative retinopathy (n = 6), (d) with no residual proliferative retinopathy after photocoagulation therapy (n = 15)), excised diabetic fibrovascular membranes (n = 19), and non-diabetic fibrocellular membranes (n = 7). The degree and pattern of immunostaining was recorded. Results - In general, VEGF was absent from the majority of normal retinas. VEGF staining was apparent in most diabetic tissues but the staining pattern was dependent on both the specificity of the antibody used and the category of tissue. Staining with the VEGF165 antibody was generally confined to endothelial cells and perivascular regions while the VEGF121,165,189 antibody was also associated with extravascular components of the inner retina. Intensity of immunostaining of diabetic eyes was dependent on the severity of retinopathy being least in diabetics with no overt retinopathy and greatest in retinas with proliferative retinopathy. Interestingly, the intensity of immunostaining in diabetic retinas which had undergone laser surgery for proliferative retinopathy was reduced to basal levels. Moderate to intense immunostaining was observed in all fibrovascular and fibrocellular membranes examined. Conclusions - This study supports a circumstantial role for VEGF in the pathogenesis of both the preclinical and proliferative stages of diabetic retinopathy.

AB - Aim - To determine the staining pattern of vascular endothelial growth factor (VEGF) at different stages of diabetic retinopathy (including post-laser photocoagulation) and to compare staining in excised fibrovascular and fibrocellular (non-diabetic) preretinal membranes. Methods - Immunohistochemical localisation of VEGF, using antibodies raised against VEGF165 and VEGF was 121,165,189, carried out on specimens of normal human retina (n = 15), diabetic retinas ((a) with no overt retinopathy (n = 19), (b) with intraretinal vascular abnormalities but no proliferative retinopathy (n = 6), (c) with active proliferative retinopathy (n = 6), (d) with no residual proliferative retinopathy after photocoagulation therapy (n = 15)), excised diabetic fibrovascular membranes (n = 19), and non-diabetic fibrocellular membranes (n = 7). The degree and pattern of immunostaining was recorded. Results - In general, VEGF was absent from the majority of normal retinas. VEGF staining was apparent in most diabetic tissues but the staining pattern was dependent on both the specificity of the antibody used and the category of tissue. Staining with the VEGF165 antibody was generally confined to endothelial cells and perivascular regions while the VEGF121,165,189 antibody was also associated with extravascular components of the inner retina. Intensity of immunostaining of diabetic eyes was dependent on the severity of retinopathy being least in diabetics with no overt retinopathy and greatest in retinas with proliferative retinopathy. Interestingly, the intensity of immunostaining in diabetic retinas which had undergone laser surgery for proliferative retinopathy was reduced to basal levels. Moderate to intense immunostaining was observed in all fibrovascular and fibrocellular membranes examined. Conclusions - This study supports a circumstantial role for VEGF in the pathogenesis of both the preclinical and proliferative stages of diabetic retinopathy.

UR - http://www.scopus.com/inward/record.url?scp=0031781305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031781305&partnerID=8YFLogxK

M3 - Article

C2 - 9713066

AN - SCOPUS:0031781305

VL - 82

SP - 561

EP - 568

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 5

ER -